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There is a growing interest in the potentially deleterious impact of antibiotics on gut
microbiota. Patients with bone and joint infection (BJI) require prolonged treatment
that may impact significantly the gut microbiota. We collected samples from patients
with BJI at baseline, end of antibiotics (EOT), and 2 weeks after antibiotic withdrawal
(follow-up, FU) in a multicenter prospective cohort in France. Microbiota composition was
determined by shotgun metagenomic sequencing. Fecal markers of gut permeability and
inflammation as well as multi-drug-resistant bacteria (MDRB) and Clostridioides difficile
carriage were assessed at each time point. Sixty-two patients were enrolled: 27 native
BJI, 14 osteosynthesis-related BJI, and 21 prosthetic joint infections (PJI). At EOT, there
was a significant loss of alpha-diversity that recovered at FU in patients with native BJI
and PJI, but not in patients with osteosynthesis-related BJI. At EOT, we observed an
increase of Proteobacteria and Bacteroidetes that partially recovered at FU. The principal
component analysis (PCoA) of the Bray–Curtis distance showed a significant change
of the gut microbiota at the end of treatment compared to baseline that only partially
recover at FU. Microbiota composition at FU does not differ significantly at the genus level
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when comparing patients treated for 6 weeks vs. those treated for 12 weeks. The use of
fluoroquinolones was not associated with a lower Shannon index at the end of treatment;
however, the PCoA of the Bray–Curtis distance showed a significant change at EOT,
compared to baseline, that fully recovered at FU. Levels of fecal neopterin were negatively
correlated with the Shannon index along with the follow-up (r2 = 0.17; p < 0.0001). The
PCoA analysis of the Bray–Curtis distance shows that patients with an elevated plasma
level of C-reactive protein (≥5 mg/L) at EOT had a distinct gut microbial composition
compared to others. MDRB and C. difficile acquisition at EOT and FU represented 20%
(7/35) and 37.1% (13/35) of all MDRB/C. difficile-free patients at the beginning of the
study, respectively. In patients with BJI, antibiotics altered the gut microbiota diversity
and composition with only partial recovery, mucosal inflammation, and permeability and
acquisition of MDRB carriage. Microbiome interventions should be explored in patients
with BJI to address these issues.
Keywords: gut microbiota, antimicrobial therapy, antibiotics, bone and joint infection, dysbiosis
INTRODUCTION
Bone and joint infections (BJI) are a public health issue
in industrialized countries (1). Different kinds of BJI exist,
depending on the pathophysiology and the route of bone
contamination. BJI may occur spontaneously, such as
hematogenous spondylodiscitis, septic arthritis, or diabetic
foot infection with osteomyelitis, and these BJI can be grouped
as “native BJI” (2, 3). Osteosynthesis-associated BJI frequently
involves the long bones, especially the tibia. Fracture-related
infections are major contributors to this group of BJI (4).
Prosthesis joint infection (PJI) is the last group of BJI that
mainly occurs in an elderly population in whom a hip or a
knee prosthesis becomes infected after its implantation (5).
Whatever the mechanism of acquisition, a BJI is considered
as one of the most difficult-to-treat bacterial infections,
as the eradication of the pathogen is challenging (1). The
multidisciplinary management and a medico-surgical approach
are crucial in all these patients. Surgery is essential in most of
them, and upon diagnosis of BJI immediately after surgery, an
intravenous, broad-spectrum empirical antimicrobial therapy is
usually started and secondarily adapted to the microbiological
culture results that reveal the pathogens involved and their
susceptibilities to antibiotics. Depending on the type of BJI
and the clinical presentation, oral antibiotics are frequently
prolonged for a total of 6 or 12 weeks of therapy (2, 3, 5, 6).
As it is one of the longest duration of antibiotics for a bacterial
infection, it could be associated with significant side effects, such
as a huge impact on the gut microbiota and the promotion of
acquired antimicrobial resistance (7–9).
It has been demonstrated that short-term antibiotic usage
strongly affects the gut microbiota. Extensive literature
describing alteration of the gut microbiota by the use of
antibiotics has bloomed over the recent years (10–13). The most
frequent manifestation is antibiotic-associated diarrhea (14),
which may be due to the direct toxin effects of antibiotics on
the intestine, altered digestive function secondary to reduced
concentrations of gut bacteria (“functional diarrhea”), or
overgrowth of pathogenic microorganisms, such as Clostridioides
difficile infection. The latter can account for most of the severe
antibiotic-associated diarrhea observed and is characterized by a
loss of the gut microbiota barrier properties, leading to frequent
C. difficile infection recurrence with high morbidity. Of note is
that one of the most effective treatments of recurrent C. difficile
infection is fecal microbiota transplantation, which aims at
restoring the fecal microbial ecosystem by transferring into the
gut a preparation of feces from a healthy donor (15).
Nowadays, the gut microbiota is considered a major
factor involved in the pathophysiology of many diseases.
The development of novel molecular technologies
coupling high-throughput metagenomic sequencing and
bioinformatics/biostatistics has overcome the limitation of
culture-based analysis of stool samples, opening a new way for
the exploration of the gut microbiota in various diseases such
as inflammatory bowel diseases (16), metabolic disorders (17),
infectious diseases (18), or, more recently, central nervous system
diseases (19). In all these conditions, an altered composition of
the gut microbiota has been described, suggesting the deleterious
effect on host physiology of modified gut microbial communities.
Infections and the use of antibiotics can cause significant and
sometimes irreversible effects on the gut microbial composition
throughout life (20, 21). The manner in which antibiotics affect
gut microbial communities can vary according to different
parameters: the route of antibiotic administration (22, 23), the
duration of treatment (24), the broad or narrow spectrum
of action of bacterial species-targeted antibiotics (25), the use
of antibiotic combinations, or the repetition of antimicrobial
treatment (26). The impact caused by antibiotics on gut
microbiota results in alteration of the bacterial diversity and gut
functions. These alterations could be transitory or could last
over time (21). After antibiotic withdrawal, the gut microbiota
has, in theory, the potential ability to return to its base state
by a mechanism called resilience (26). However, resilience after
prolonged antibiotic exposure has been poorly evaluated.
Antibiotics and gut microbiota modifications have also
been associated with local alterations in gut physiology with
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inflammation and increased permeability (27). To explore these
aspects within the clinical model of BJI treatment, we assessed
the dynamics of various markers of intestinal inflammation such
as fecal neopterin and calprotectin, which are increased in an
inflammatory context (28, 29) and zonulin, the only known
protein that regulates intercellular tight junctions (30).
The main concern with prolonged antibiotic treatment is
the emergence of antimicrobial resistance and its spread into a
patient’s environment (31). Extensive use of antibiotics in the
last 40 years has systematically led to the emergence of bacterial
resistance and development of nosocomial infections, mainly
due to methicillin-resistant Staphylococcus aureus (MRSA)
in the 1990s and now particularly due to commensals
of the gut microbiota such as multidrug-resistant (MDR)
Enterobacteriaceae. These hospital-acquired infections are causes
of considerable morbidity and mortality in many industrialized
countries and are one of the major concerns of public health
issues and threats. In the last 10 years, MDR Enterobacteriaceae,
particularly MDR Escherichia coli and Klebsiella pneumoniae,
also emerged as community-acquired infections (i.e., infections
contracted outside of a healthcare setting) (32, 33). Antibiotic
treatments may facilitate the acquisition of MDR bacteria
(MDRB) in the gut that can disseminate in the patient’s
environment (31).
In this study, we aimed to investigate for the first time the
microbiological, clinical, and biological consequences on the
gut microbiota and its host of prolonged antibiotic treatment
in patients with different types of BJI. Antibiotic-related gut
microbiota modifications and its resilience were assessed using
shot-gun metagenomic sequencing after different treatment
durations (6 weeks compared to 12 weeks) and different
types of antibiotics, while potential association of the gut
microbiota composition was investigated with (i) gut markers of
inflammation and permeability, (ii) C-reactive protein (CRP), a
systemic marker of inflammation that usually followed during
BJI, and (iii) the acquisition of MDRB or C. difficile fecal carriage.
MATERIALS AND METHODS
Study Description
We performed a multicentric prospective interventional study in
France called InterventiOnal Study of Bone and Joint Infections
Related Gut DysbiosIS (OSIRIS) (NCT03011502; EudraCT 2016-
003247-10) from January 2017 to September 2017. Five recruiting
centers belonging to the CRIOAc network, a nationwide network
of clinical centers dedicated to the management of complex BJI,
were selected: Lyon (Hospices Civils de Lyon, CRIOAc Lyon),
Bordeaux (CRIOAc GSO), Nantes (CRIOGO), Paris (CRIOAc
Paris), and Lille-Tourcoing (CRIOAc G4).
Ethics
Patients highly suspected of BJI were informed and enrolled after
their signature of written consent in the OSIRIS protocol. Patient
follow-up was designed as part of standard care, with some
interventions dedicated to the specific needs of the protocol.
This study was reviewed and approved by a regional ethics
committee (Comité de Protection des Personnes SUD-EST II;
69HCL16_0623). The study was also approved by the French
Health authority (Agence Nationale de Sécurité du Médicament
et des produits de Santé, ANSM).
Data Collection
Clinical data and stool collection were performed at baseline
visit (B) within 24 h before starting the antibiotics, at the end of
the treatment (EOT), and at 2 weeks after antibiotic withdrawal
during a follow-up visit (FU). An electronic case report form
(e-CRF) was created, and clinical data and the results of the
serum CRP measurements were prospectively collected during
follow-up using the ClinSightTM software.
Data that support the findings of the study are available from
the corresponding author upon reasonable request.
Stool Collection and Fecal Microbiome
Analysis
The patients collected their stools using a dedicated clean
container system, ensuring stool conservation (Fecotainer R©)
within 48 h prior to freezing. The samples were then snap-
frozen in triplicates of 1 g and stored at−80◦C. At the end
of the follow-up of the last patient, the samples were sent to
Eurofins Inc., for DNA extraction and shotgun analysis. Genomic
DNA was extracted from the fecal samples using the Qiagen
QIAamp Fast DNA stool mini-kit after bead beating. Positive
(Escherichia coli) and negative (no template, i.e., water) controls
have been added throughout the process, from DNA extraction
to sequencing, to validate the successful completion of each step.
Sequencing library was constructed for each DNA sample using
the TruSeq Nano DNA Library Prep kit (Illumina) according to
the manufacturer’s instructions. Libraries were then sequenced in
paired-end (2× 125 bp) HiSeq2500 v4 (Illumina) runs.
Bioinformatics analyses were performed on the Gut Print R©
platform with the in-house MgRunner v1.1.2 pipeline. In
brief, after quality filtering using Trimmomatic (34), host
sequence removal was performed using Bowtie2 (35). To
ensure comparability, all samples were rarefied to the same
sequencing depth, i.e., 5,000,000 paired-end sequences per
sample. Taxonomic profiling was then performed with Kraken
v.0.10.5-beta (36) and the RefSeq genomic database (2015 release,
http://www.ncbi.nlm.nih.gov/refseq/). The measurement of α-
and β-diversity indexes was performed in R Statistical Software
((37), version 3.4.4, http://www.R-project.org) using vegan and
phyloseq packages. Identification of marker taxa for the different
groups was achieved through differential abundance analysis
using linear discriminant analysis effect size (38).
Neopterin, Calprotectin, Zonulin, and IgA
Quantification in Stools
Biological markers of gut permeability and inflammation
were monitored at each time point. At the end of the
follow-up of the last patient, the samples were sent to
the biochemistry laboratory of the HCL Centre Hospitalier
Lyon Sud for ELISA-related techniques of analysis to be
performed. Supernatants were obtained in the laboratory and
then run to quantify sIgA (ImmunoChrom kit RIC6100—
BioVendor), neopterin (kit neopterin ELISA Ref59321—IBL
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International), calprotectin (fCAL RefEKCAL2—Bülhmann),
and zonulin (RefK5600—ImmunDiagnostik), according to the
manufacturer’s instructions.
Fecal MDRB Cultures and Antibiogram
Analysis
Fecal swabs were sampled at each specified patient visit and then
sent prospectively to the IAI for fresh cultures on specific gelose
media to evaluate the fecal portage of MDRB such as extended-
spectrum beta-lactamases-producing Enterobacteriaceae (ESBL),
carbapenemase-producing Enterobacteriaceae, MRSA, and C.
difficile. When positive (i.e., detection of a growth) in
selective chromogenic media (ChromID?: MRSA, ESBL, OXA48
and CARBA SMART, Biomérieux, Marcy-l’étoile, France),
antibiograms and mass spectrometry were done on isolates
to specify the minimum inhibitory concentrations of specific
antibiotics and specify the isolates’ identification (genus/species).
When positive for ESBL, patient samples were thawed to quantify
ESBL and total Gram-negative bacteria.
Statistical Analysis
Linear regression, Wilcoxon, and Mann–Whitney test were
performed with Prism (GraphPad R©, version 8.4.3, GraphPad
Software, La Jolla California, USA; www.graphpad.com). P values
are indicated in the graphs unless specified in the legend.
Permutational multivariate analysis of variance (PERMANOVA)
was performed with the R Statistical Software using the Adonis
package. Analyses were performed both at the genus and




At the end of the inclusion period, 62 patients were enrolled,
including 27 with a native BJI, 14 with an osteosynthesis-related
BJI, and 21 with a PJI. The patients’ characteristics are detailed
in Table 1, and the patients’ characteristics during the study
are presented in Table 2. Each patient received personalized
antimicrobial therapy, from empirical to targeted treatment,
depending on the microbiological culture results and local and
recommended treatment strategy. A total of 16 different types of
antibiotic were used. The most frequent one was fluoroquinolone
(FQ) (n = 47), a category that includes ofloxacin, levofloxacin,
and ciprofloxacin (Figure 1A). After excluding extreme values,
the duration of antimicrobial treatment was divided into two
different groups corresponding to the two mainly recommended
antibiotic duration in BJI: a “6 weeks” group (n= 20; between 41
to 60 days) and a “12 weeks” group (n = 15; between 81 and 100
days; Figure 1B).
Antibiotics Alter Gut Microbiota Diversity
and Composition With Partial Recovery 2
Weeks After Antibiotic Withdrawal
BJI antimicrobial therapies alter the gut microbiota diversity
as demonstrated by a decrease of the Shannon index and
richness between B and EOT (Figures 2A,B). However, after
2 weeks of antibiotic withdrawal, the microbiota diversity
increased but remained at lower values than those before
treatment (Figures 2A,B). Interestingly, resilience differed
between the three different subpopulations of BJI (Figure 2C
and Supplementary Figure 1). Indeed native BJI showed no
significant difference between B and FU for the Shannon Index
and richness, whereas osteosynthesis-related BJI presented only
a partial recovery at FU for both parameters. Patients with PJI
presented a lower Shannon index at FU (mean = 3.0 ± 0.6)
compared to EOT (mean = 3.2 ± 0.4) and B (mean = 3.6 ±
0.6), even if it did not reach statistical significance probably
because of the small sample size (Figure 2C). Interestingly, when
considering the gut microbiota composition using taxonomic
analysis, we observed an increase of Proteobacteria that partially
recovered at FU (relative abundance at B: 7.2%, EOT: 13.5%, and
FU: 10.2%).











Male (n, %) 17 (63) 10 (71.5) 13 (62) 40 (64.5)
Age (years)a 56.1 (13.2) 51.8 (17.6) 65.3 (9.1) 58.6 (14.1)
Antibiotic duration (days)a 58.8 (26.7) 69.8 (28.4) 68.3 (29.3) 64.5 (27.8)
BMI (mean)a 25.6 (6.5) 28.1 (5.8) 29.5 (7.0) 27.5 (6.6)
MDRB carriage at baseline (n, %)
- MRSA 3 (11.1) 1 (7.1) 5 (23.8) 9 (14.5)
- ESBL-producing 0 0 0 0
- Enterobacteriaceae 3 (11.1) 1 (7.1) 5 (23.8) 9 (14.5)
- HREB 0 0 0 0
Clostridioides difficile carriage at baseline (n, %) 1 (3.7) 0 0 1 (1.6)
aData are expressed as mean (standard deviation).
BJI, bone joint infection; PJI, prosthesis joint infection; BMI, body mass index; MDRB, multidrug-resistant bacteria; MRSA, methicillin-resistant Staphylococcus aureus; ESBL,
extended-spectrum beta-lactamases; HREB, highly resistant emergent bacteria.
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TABLE 2 | Patients’ characteristics along the study.
BJI population Baseline End of treatment Follow-up Normal values
Feces weight (g) 60.5 (n = 54) 61.5 (n = 46) 72 (n = 46) 100–200
MDRB fecal carriage (%) 17.54 25.00 39.13 NA
DNA extraction 1.04 ± 0.14 0.69 ± 0.12 0.84 ± 0.14 NA
Neopterina (pmol/g) 97.7 494.7b 285.4b 55
Calprotectina (µg/g) 128.6 49.4b 53.5b <50
Zonulina (ng/mL) 85.2 128.1b 131.0b 61 ± 46
IgAa (µg/g) 2,187.6 2,235.5 2,204.7 2,000
CRPc (mg/L) 50.3 6 6.6 <5
aQuantification in fecal supernatants.
bSignificant p value <0.05, Wilcoxon test.
cBlood quantification.
BJI, bone and joint infection; MDRB, multidrug-resistant bacteria; IgA, immunoglobulin A; CRP, C-reactive protein; NA, not applicable.
FIGURE 1 | Types of antibiotics and treatment duration in the OSIRIS cohort. (A) Distribution of the different types of antibiotics used. (B) Distribution of the antibiotic
durations used.
In PJI, there was also a decrease of Firmicutes relative
abundance compared to baseline (relative abundance at B:
36.1%, EOT: 28.4%, and FU: 26.5%; Figure 2D). Considering
the whole population of BJI, the principal coordinate analysis
(PCoA) of the Bray–Curtis distance showed significant changes
of the gut microbiota at the end of treatment that only
partially recovered at FU (Figure 2E). The compilation of
the 20 bacteria that varied the most in relative abundance
between B and EOT and B and FU for each group of patients
is presented in Supplementary Figures 2A,B, respectively. A
linear discriminant analysis effect size showing species that
supported the differences between baseline and EOT is also
shown Supplementary Figure 3. As PJI usually concern older
patients for whom the microbiota may show a lower alpha-
diversity, we evaluated if the age at baseline could be correlated
with the Shannon index at different times of treatment. No
correlation was found between age and Shannon index at B,
EOT, and FU nor between body mass index and Shannon index
(Supplementary Figure 4).
No Difference of Gut Microbiota Diversity
and Recovery After Antibiotic Withdrawal
Between 6 and 12 Weeks of Treatment
Taxonomic analysis showed that the microbiota composition
at FU did not differ significantly at the phylum level
when comparing patients treated for 6 and 12 weeks with
antibiotics (Figure 2D). Considering alpha-diversity, there was
no significant difference between 6 and 12 weeks at EOT
and FU (Figures 3A,B). Moreover, the Shannon index at EOT
and FU did not correlate with antibiotic duration (Figure 3C).
Accordingly, the PCoA of the Bray–Curtis distance showed
that there was no difference in terms of recovery when
comparing FU to baseline, whether antibiotic withdrawal
occurred after 6 or 12 weeks of treatment (Figures 3D,E).
However, analysis at the species level showed actual differences
underlying potentially distinct pathophysiological functions
(Supplementary Figure 2). Of note is the fact that no difference
was found when comparing the composition of the gut
Frontiers in Medicine | www.frontiersin.org 5 March 2021 | Volume 8 | Article 586875
Levast et al. Antimicrobial Therapy and Gut Microbiota
FIGURE 2 | Effect of antibiotics on the gut microbiota in bone joint infection (BJI). (A) Shannon index (genus level) at three times of sampling; Wilcoxon test. (B)
Richness (genus level) at three times of sampling; Wilcoxon test. (C) Shannon index at three times of sampling according to the type of BJI; Wilcoxon test for paired
comparison, Mann–Whitney analysis for inter-group comparisons. (D) Global composition of bacterial microbiota at the phylum level. (E) Beta diversity. Principal
coordinate analysis of Bray–Curtis distance at three different times of sampling; permutational multivariate analysis of variance. B, baseline; EOT, end of treatment; FU,
follow-up. *p < 0.05; **p < 0.01; ***p < 0.001; ****p < 0.0001.
microbiota for 6 and 12 weeks of treatment at any timepoint (data
not shown).
Treatment by Fluoroquinolone Was
Associated With Significant Changes of
Gut Microbiota Composition That Rapidly
Recover After Antibiotic Withdrawal
The use of FQ was associated with a lower richness and Shannon
index at the end of antibiotic treatment (Figures 4A,B). However,
diversity rapidly recovered after FQ withdrawal, suggesting a
high but transient impact of FQ on gut microbiota. Accordingly,
the PCoA of the Bray–Curtis distance showed significant changes
of the gut microbiota composition at the end of treatment in the
FQ-treated group that recovered at FU, whereas no difference was
found between baseline, EOT, and FU for patients that did not
receive FQ (Figures 4C,D).
Fecal Markers of Mucosal Inflammation
Were Increased at the End of Treatment
and Correlated With Microbiota
Alpha-Diversity
Fecal neopterin and fecal calprotectin, two markers of mucosal
inflammation, were significantly increased at the end of
treatment, with sustained changes that persisted at 2 weeks
after antibiotic withdrawal (Figures 5A,B). However, only fecal
neopterin reached a clinically relevant range of variation (≥200
pmol/g). Fecal zonulin also showed a significant increase at
the end of treatment that persisted after 2 weeks, suggesting
an increased intestinal permeability that lasted after exposure
to antibiotics (Figure 5C). In line with a possible modification
of mucosal immunity, fecal immunoglobulin A was also
significantly modified at FU (Figure 5D). Strikingly, the level
of fecal neopterin negatively correlated with the Shannon index
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FIGURE 3 | Impact of antibiotic duration on the gut microbiota composition. (A) Shannon index distribution (genus level) at the end of treatment and at follow-up (15
days after antibiotic withdrawal) according to antibiotic duration; Wilcoxon test for paired comparison and, Mann-Whitney test for inter-group comparisons. (B)
Richness distribution (genus level) at the end of treatment and at follow-up (15 days after antibiotic withdrawal) according to antibiotic duration; Wilcoxon test for
paired comparison and, Mann-Whitney test for inter-group comparisons. (C) Correlation between the Shannon index and antibiotic duration at EOT and FU; simple
linear regression. Principal coordinate analysis of Bray–Curtis distance at three different times of sampling for (D) patients treated for 6 weeks with antibiotics (41 to 60
days) or (E) 12 weeks with antibiotics (81 to 100 days); permutational multivariate analysis of variance. B, baseline; EOT, end of treatment; FU, follow-up. *p < 0.05;
**p < 0.01; ***p < 0.001.
all along the follow-up (Figure 5E, r2 = 0.17; p < 0.0001). The
evolution of fecal markers in each subpopulation of BJI is detailed
in Supplementary Figure 5.
Systemic CRP Decreased With
Antimicrobial Treatment, but Elevated CRP
at EOT Correlated With Fecal Neopterin
and Was Associated With a Distinct Gut
Microbiota Composition
Systemic CRP significantly decreased from B to ETO with
antimicrobial treatment and from B to FU (Figure 6A). As we
hypothesized that residual systemic inflammation evaluated by
CRP could be associated with microbiota alterations, we assessed
the correlation between CRP and fecal neopterin, the markers of
inflammation that varied the most at EOT. Of note is the fact
that 28 patients had CRP ≥5 mg/L at EOT despite a favorable
outcome of the BJI. We found that CRP at EOT correlated
with fecal neopterin, and this suggests that residual systemic
inflammation could be associated with gut inflammation rather
than with a relapse of the BJI (Figure 6B). Moreover, the
PCoA analysis of the Bray–Curtis distance showed that patients
with elevated CRP at EOT presented a distinct gut microbial
composition (PERMANOVA, p = 0.034) with an increase in
Fusobacterium species (Figure 6C, Supplementary Figure 6).
MDRB Fecal Carriage in the Fecal
Microbiota of Patients Can Appear After
Antibiotic Withdrawal
Among the BJI population, nine patients were positive for
MDRB fecal carriage at baseline (9 ESBL, 0 MRSA, 0 VRE;
Figure 7A, Table 1). Among the 35 patients negative for MDRB
at baseline and who performed MDRD screening at EOT,
acquisition of ESBL was detected for six patients (6/35; 17.1%).
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FIGURE 4 | Impact of the use of fluoroquinolone (FQ) on gut microbiota composition. (A) Shannon index distribution (genus level) at the end of treatment and at
follow-up (15 days after antibiotic withdrawal) according to exposition to FQ; Wilcoxon test for paired comparison and, Mann-Whitney test for inter-group
comparisons. (B) Richness (genus level) at the end of treatment and at follow-up (15 days after antibiotic withdrawal) according to exposition to FQ; Wilcoxon test for
paired comparison and, Mann-Whitney test for inter-group comparisons. Principal coordinate analysis of Bray–Curtis distance at three different times of sampling for
(C) patients treated with FQ or (D) without FQ; permutational multivariate analysis of variance. B, baseline; EOT, end of treatment; FU, follow-up. *p < 0.05;
**p < 0.01; ***p < 0.001.
Additional acquisition of MDRB at FU was observed for five
patients (5/35, 14%: three ESBL, one carbapenem-resistant
Enterobacter, and one rectal MRSA). Concerning C. difficile,
one patient had an asymptomatic carriage at baseline and
two other patients acquired C. difficile during the study (2/35,
5.7%). Overall, MDRB and C. difficile acquisition at EOT
and FU represented 20% (7/35) and 37.1% (13/35) of all
MDRB/C. difficile-free patients at the beginning of the study,
respectively (Figure 7A). Of interest is that the quantification
of MDRB-positive samples at FU in comparison to baseline
clearly indicated an increased proportion of ESBL bacteria
among fecal gram-negative bacteria (Figure 7B). Interestingly,
among the nine patients with an ESBL carriage at baseline,
five were still positive at EOT (5/9, 55.6%) and six at FU (6/9,
66.7%). MDRB carriage was not associated with differences
in term of resilience (Bray–Curtis index between B and
FU; Figure 7C) nor with different levels of fecal neopterin
(Figure 7D).
DISCUSSION
This study explores, for the first time, how prolonged
antibacterial therapy can disrupt the gut microbiota composition
in the context of BJI. First, our data show that antibiotic treatment
induced a significant loss of microbiota diversity that rapidly
recovered at 2 weeks after the end of treatment for native and
PJI but not for osteosynthesis-related BJI. These modifications
were associated with distinct variations of bacterial phyla, in
particular, with an increase of Proteobacteria and Bacteroidetes
that did not fully recover at 2 weeks after antibiotic withdrawal.
Second, comparing 6 to 12 weeks of antibiotic treatment did not
show amajor impact of treatment duration on the gut microbiota
composition at the genus level and on microbiota diversity or
resilience after treatment. In contrast, FQ was associated with
a greater impact on microbiota diversity compared to other
antibiotics, with a high resilience at FU. Third, fecal markers of
inflammation were increased after antibiotic treatment, with a
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FIGURE 5 | Correlation between markers of gut inflammation, permeability, and microbiota alpha-diversity. Values of fecal neopterin (A), fecal calprotectin (B), fecal
zonulin (C), fecal immunoglobulin A (D) at different time points; Wilcoxon test. (E) Correlation between fecal neopterin and the Shannon index (genus level) all along
the study; simple linear regression. B, baseline; EOT, end of treatment; FU, follow-up. *p < 0.05; **p < 0.01; ***p < 0.001; ****p < 0.0001.
correlation between fecal neopterin and both microbial alpha-
diversity and serum level of CRP. Moreover, patients with an
elevated CRP presented a distinct gut microbial composition
when compared to the others. This suggests that modifications
of the gut microbiota by antibiotics could be associated with low-
grade mucosal inflammation and residual systemic inflammation
that possibly persisted at least 2 weeks after antibiotic withdrawal.
Finally, as expected, antibiotic treatment was associated with
MDRB acquisition and, particularly, ESBL emergence.
The potential effects of antibiotics on gut microbiota
communities have been described for various treatments but
only on small cohorts and rarely after prolonged antibiotic
treatments (39). As observed in our work, loss of bacterial
diversity was commonly reported particularly for molecules that
target anaerobes with possible long-lasting effects even after a
short course of antibiotic exposure (40). Indeed Jernberg and
colleagues reported significant durable changes in Bacteroides
clonal diversity up to 2 years after 7 days of clindamycin
treatment (25), whereas others reported limited changes at 4
weeks after a short-term ciprofloxacin treatment (41).
Moreover, the effect of antibiotics on bacterial communities
varies between individuals. For example, repetitive ciprofloxacin
exposure amplifies microbial changes but only for some subjects
(26). Thus, pre-treatment microbial diversity may account for
differences in microbial communities’ resilience and long-term
effects of antibiotics. This initial dysbiosis/eubiosis state at the
beginning of treatment may account for the rapid recovery of
the gut microbial diversity of patients with native BJI compared
to others. Indeed osteosynthesis-related BJI and PJI involved
patients with complex infections and often previous antibiotic
exposures. Even if the overall gutmicrobiota diversity can recover
after treatment, definitive loss of some bacterial strains persists
over time (21). Indeed, in our data, alpha-diversity seemed to
be almost back to initial levels at 2 weeks after the end of
treatment, but permanent changes in the abundance of specific
species remained, of which the pathophysiological consequences
remain unknown. However, functional redundancy supported by
different bacterial species may counteract the possible effects of
these permanent changes in microbiota composition (42).
When comparing the 6- and 12-week groups by PCoA analysis
of the Bray–Curtis distance or when considering the correlation
between antibiotic duration and alpha-diversity, the duration of
treatment did not seem to affect the overall microbiota diversity
or the resilience of the gut microbiota after antibiotic withdrawal.
One possible explanation could be that 6 weeks of treatment
is a sufficient amount of time to reach a microbial steady state
that may persist with only small variations if antibiotics are
prolonged. Indeed doses of antibiotics in BJI are, most of the
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FIGURE 6 | Correlation between systemic and mucosal markers of inflammation. (A) Evolution of the plasmatic level of C-reactive protein (CRP) at different time
points. (B) Correlation between fecal neopterin and plasmatic CRP; simple linear regression. (C) Principal coordinate analysis of Bray–Curtis distance between
patients with each sample colored according to plasmatic CRP level at the end of treatment; permutational multivariate analysis of variance. B, baseline; EOT, end of
treatment; FU, follow-up. *p < 0.05; **p < 0.01; ***p < 0.001; ****p < 0.0001.
time, high because of the limited diffusion into the bones of the
majority of antibacterial therapies. This combination of high dose
and prolonged exposure may favor a rather rapid achievement of
a steady state of the gutmicrobiome that could be stable over time
as the treatment is continued.
As described in numerous works, antibiotic exposure was
associated with the selection of MDRB in our population.
Notably in our cohort, the proportion of patients positive for
MDRB or C. difficile reached almost 40% at FU. Even if MDRB
decolonization is known to occur spontaneously after antibiotic
withdrawal (43), increasing the amount of data suggests that
genes for antibiotic resistance can persist for a long time once
selected (44), which suggests a long-lasting effect of antibiotic
treatement for patients with BJI.
One other striking result of this study is the identification of
a correlation between markers of gut inflammation such as fecal
neopterin and microbiota diversity. In rats, antibiotic exposure
has already been associated, as we observed, with an increase
of gut permeability and increased plasma levels of haptoglobin,
a precursor of zonulin (45). Interestingly, the authors reported
similar modifications of the gut microbiota with an increase of
Proteobacteria and a general decrease of microbiota diversity.
In the same line, Feng et al. (27) reported similar modifications
of gut permeability after antibiotic treatment in mice, associated
with the activation of the NLRP3 inflammasome and autophagy.
We also found that residual systemic inflammation evaluated
by CRP correlated with fecal neopterin and, in consequence,
with the potential persistence of microbiota alterations at the end
of antibiotic treatment. It is of importance, as CRP is usually
monitored to evaluate the BJI’s response to antibiotics. Indeed
some physicians consider that if CRP is still elevated at the end
of treatment, it could be due to bacterial persistence at the site
of bone infection, leading to consideration of prolongation of the
antibiotic treatment. However, data indicate that the CRP level
at the end of treatment is not predictive of a persistent infection
(46, 47). Thus, our results raise the hypothesis that abnormal CRP
at the end of the treatment could be a potential marker of gut
barrier dysfunction associated with microbial dysbiosis. Further
data are required to confirm this hypothesis.
Antibiotic impact on the gut microbiota has potential long-
term effects which suggest several measures to correct or prevent
these changes. The best way would be to minimize the use of
antibiotics, preferentially by using in situ antibiotics or using
antibiotics with a narrow spectrum to limit the impact on
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FIGURE 7 | Fecal multi-drug-resistant bacteria (MDRB) and Clostridioides difficile carriage. (A) Proportion of patients with a positive fecal carriage (culture) at different
time points. (B) EBSL as percentage of the total of all Gram-negative bacteria (aerobic culture). (C) Bray Curtis distance between baseline and 15 days after antibiotic
withdrawal (FU) according to the carriage of MDRB; Mann–Whitney test. (D) Fecal neopterin at baseline and 15 days after antibiotic withdrawal (FU) according to the
carriage of MDRB; Mann–Whitney test. B, baseline; EOT, end of treatment; FU, follow-up; ESBL, extended-spectrum beta-lactamases; MRSA, methicillin-resistant
Staphylococcus aureus. *p < 0.05; **p < 0.01; ***p < 0.001.
the gut microbiota. However, in many infections such as BJI,
antibiotics cannot be replaced, and long-term systemic treatment
at high dosage is mandatory to cure patients. In these situations,
microbe-based therapy to counteract the deleterious ecological
effects of such treatments could be of interest, especially in
selected populations at risk of non-recovery (elderly, personal
medical history of C. difficile infection, low microbiota diversity,
possibly osteosynthesis-related BJI, etc.). When specifically
targeting the gut microbiota, different tools are commonly used.
Either selected microbes (bacteria and/or fungi) can be added
as probiotics or specific molecules (prebiotics) can be used to
promote specific species of interest, but as the gut microbiota is
a complex ecosystem, such tools may miss significant network
interactions at the level of bacterial species or between different
kingdoms (bacteriophages and fungi, for example).
Moreover, there are some concerns about probiotics, as they
are composed of only a few bacterial species, and their capacity
to positively impact antibiotic-associated dysbiosis is debatable.
Fecal microbiota transplantation is nowadays the only
treatment that permits the engraftment of a complex ecosystem
with proven functional benefits. It consists of the transfer
of the fecal microbial ecosystem of a healthy donor to a
recipient in order to restore gut homeostasis. Evaluation of fecal
microbiota transplantation in various pathological conditions is
now blooming, with contrasting results extending the need to
validate the administration modality and long-term safety (48).
Our study has some limitations. First, the relatively low
number of evaluated patients may account for a lack of power
especially in subgroup analysis. Moreover, some patients did not
perform stool sampling at all time points, which may also have
induced some bias. However, it is, to our knowledge, one of
the largest clinical studies evaluating the effects of prolonged
antimicrobial therapy on the gut microbiota. The use of rectal
swabs may facilitate recruitment and increase patient adherence
to develop larger studies. Furthermore, evaluation of microbial
composition and inflammatory markers at a more distant time
point after antibiotic withdrawal would be of great interest to
assess the long-term impact of antibiotics on the gut ecosystem
and mucosal physiology.
In conclusion, to our knowledge, this is the first study
that explores the impact of prolonged antibiotic treatment
on gut microbiota in the context of BJI. As expected,
antibiotics significantly altered the gut microbiota diversity
and composition, with a rapid but partial recovery observed
at 2 weeks after antibiotic withdrawal. Antibiotic duration or
the use of FQ did not seem to affect this resilience. These
modifications were associated with an increase in markers of
mucosal inflammation and gut permeability and elevated levels
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of CRP. Further studies are needed to explore these possible
links and their impact on resilience. Finally, as illustrated in our
cohort, acquisition of MDRB remains one the most challenging
side effects of long-term exposure to antibiotics. Innovative
microbe-based therapies could be a promising tool to address
these issues.
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